The DOI matches its Crossref record; 282 of the 286 references it cites were found in a registry or an index.
Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets?
Abstract
Sarcopenic obesity (SO) is a condition characterized by the occurrence of both sarcopenia and obesity and imposes a heavy burden on the health of the elderly. Controversies and challenges regarding the definition, diagnosis and treatment of SO still remain because of its complex pathogenesis and limitations. Over the past few decades, numerous studies have revealed that myokines secreted from skeletal muscle play significant roles in the regulation of muscle mass and function as well as metabolic homeostasis. Abnormalities in myokines may trigger and promote the pathogenesis underlying age-related and metabolic diseases, including obesity, sarcopenia, type 2 diabetes (T2D), and SO. This review mainly focuses on the role of myokines as potential biomarkers for the early diagnosis and therapeutic targets in SO.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hormones were identified and subsequently leveraged for use as therapeutics throughout the 20th century but it is only in more recent times that numerous families of secreted signaling molecules bearing the suffix “‐kines” such as myokines, 243 osteokines, adipokines, 244 and hepatokines 245 have been identified. 242”
From The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments (2022) · cites this paper as [243]
Citations
Cites
1 retracted
THIS ARTICLE HAS BEEN RETRACTED Exercise induces interleukin‐8 expression in human skeletal muscle
Akerstrom, T. C. A., Steensberg, A., Keller, P., Keller, C., Penkowa, M., & Pedersen, B. K. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.077610 · Cited by 130
RetractedAbarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
Cruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Muscles, exercise and obesity: skeletal muscle as a secretory organ
Pedersen, B. K., & Febbraio, M. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.49 · Cited by 2,909
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
Research works printed but not linked: 4
- Batsis, 2018, Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies, Nat. Rev. Endocrinol., 14, 513, 10.1038/s41574-018-0062-9 · DOI · Paper page
- Di Meo, 2017, Skeletal muscle insulin resistance: role of mitochondria and other ROS sources, J. Endocrinol., 233, R15, 10.1530/JOE-16-0598 · DOI · Paper page
- Kostrominova, 2016, Role of myokines in the maintenance of whole-body metabolic homeostasis, Minerva Endocrinol., 41, 403
- Lipina, 2017, Lipid modulation of skeletal muscle mass and function, J. Cachexia. Sarcopenia Muscle, 8, 190, 10.1002/jcsm.12144 · DOI · Paper page
Cited by
Sorted by citations
Bilski, J., Pierzchalski, P., Szczepanik, M., Bonior, J., & Zoladz, J. A. (2022) · Cells · doi:10.3390/cells11010160 · Cited by 271
“Disorders in myokine secretion may play a role in the pathogenesis of age-related and metabolic diseases, including obesity, T2D, sarcopenia, and SO [111,243,244].”
BackgroundLiu, C., Wong, P. Y., Chung, Y. L., Chow, S. K., Cheung, W. H., Law, S. W., Chan, J. C. N., & Wong, R. M. Y. (2023) · Obesity Reviews · doi:10.1111/obr.13534 · Cited by 247
“The pathogenetic roles of these biomarkers in SO and SO-related diseases require further investigation to explore whether they are potential therapeutic targets.(131) Simi-”
BackgroundSkeletal muscle energy metabolism in obesity
Mengeste, A. M., Rustan, A. C., & Lund, J. (2021) · Obesity · doi:10.1002/oby.23227 · Cited by 141
“Moreover, it is quite likely that other myokines with therapeutic potential for treating obesity and associated metabolic abnormalities will be explored in the future (89).”
BackgroundExercise therapy for people with sarcopenic obesity: myokines and adipokines as effective actors
Alizadeh Pahlavani, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.811751 · Cited by 145
“Myokines act as a mediator between skeletal muscle and other tissues (13).”
BackgroundInfluentialSarcopenia and Cognitive Function: Role of Myokines in Muscle Brain Cross-Talk
Scisciola, L., Fontanella, R. A., Surina, S., Cataldo, V., Paolisso, G., & Barbieri, M. (2021) · Life · doi:10.3390/life11020173 · Cited by 153
“It was also demonstrated that LIF, via PKB/extracellular signal-regulated-mediated c-fos induction, protects against amyloid β-induced neurotoxicity [112].”
Background
Metadata
- Authors
- Guo, A., Li, K., & Xiao, Q.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Corresponding author
- Xiao, Qian
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 139
- Pages
- 111022
- ISSN
- 0531-5565 (ISSN-L)
- OpenAlex
- W3043914821
- Cited by
- 83
- References
- 286
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 9 · 2023: 20 · 2022: 16 · 2021: 12 · 2020: 1
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Gerontology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chongqing Medical University
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- sarcopenic obesity, myokines, skeletal muscle, biomarkers, therapeutic target, sarcopenia, obesity, type 2 diabetes, aging, metabolic homeostasis, muscle mass and function
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Humans, Obesity, Biomarkers, Muscle, Skeletal, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
